Also listed under Genital Neoplasms, Female, Ovarian Diseases
ClinicalTrials.gov term: Ovarian Neoplasms
109 trials changed in the last 30 days: 4 stopped, 52 with notable changes, 53 with minor changes only.
Trial terminated
Also in this update: Primary completion date changed from estimate of Aug 12, 2026 to Sep 30, 2025; Final enrollment: 21 participants (planned 66)
USWM CT, LLCPhase 2 NCT05601752 Registry history of NCT05601752 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Final enrollment: 3 participants — 3% of the 120 planned; Primary completion date changed from estimate of Sep 1, 2027 to Jan 30, 2026
SystImmune Inc.Phase 1 NCT06714617 Registry history of NCT06714617 on ClinicalTrials.gov (opens the registry)
Withdrawn before enrolling
Georgetown UniversityPhase 2 NCT05479045 Registry history of NCT05479045 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Final enrollment: 6 participants — 8% of the 75 planned; Primary completion date changed from estimate of Oct 2025 to Aug 1, 2024
Centre Hospitalier Metropole SavoieNot applicable NCT05833321 Registry history of NCT05833321 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 2026 to Jan 2027
BicycleTx LimitedPhase 1/2 NCT04561362 Registry history of NCT04561362 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 17, 2029 to Jul 22, 2030
And 1 more change in the last 30 days
GlaxoSmithKlinePhase 3 NCT07286266 Registry history of NCT07286266 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 2026 to Nov 2027
Also in this update: Enrollment reopened; Enrollment increased: 120 → 150 participants
Volastra Therapeutics, Inc.Phase 1 NCT06084416 Registry history of NCT06084416 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 21, 2026 to Dec 15, 2027
National Cancer Institute (NCI)Phase 2 NCT03587311 Registry history of NCT03587311 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 25, 2027 to Nov 8, 2028
Also in this update: Study completion pushed from Nov 30, 2027 to Nov 8, 2028
Regeneron PharmaceuticalsPhase 1/2 NCT04590326 Registry history of NCT04590326 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Oct 31, 2027
Also in this update: Enrollment increased: 292 → 473 participants; Study completion pushed from Jun 1, 2027 to Mar 30, 2028
Bicara TherapeuticsPhase 1 NCT04429542 Registry history of NCT04429542 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Oct 2027 to Jun 2028
Also in this update: Study completion pushed from Jul 2028 to Dec 2028
Base Therapeutics (Shanghai) Co., Ltd.Early Phase 1 NCT07657416 Registry history of NCT07657416 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Apr 20, 2030
Also in this update: Enrollment increased: 470 → 540 participants; Study completion pushed from Mar 21, 2028 to Jul 22, 2030
SystImmune Inc.Phase 1 NCT05983432 Registry history of NCT05983432 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 20, 2026 to Sep 20, 2027
Memorial Sloan Kettering Cancer CenterNot applicable NCT05053230 Registry history of NCT05053230 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 2026 to Jul 2027
Also in this update: Enrollment closed, study ongoing; Trial sites reduced: 8 → 5 locations
Instituto do Cancer do Estado de São PauloPhase 2 NCT06638931 Registry history of NCT06638931 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 16, 2028 to Aug 6, 2028
City of Hope Medical CenterNot applicable NCT07741968 Registry history of NCT07741968 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 2026 to Oct 25, 2027
Also in this update: Primary endpoint(s) modified; Enrollment increased: 50 → 120 participants
Assiut UniversityNot specified NCT06777147 Registry history of NCT06777147 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 2026 to Aug 2027
Northwestern UniversityNot applicable NCT05990426 Registry history of NCT05990426 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 10, 2024 to Sep 28, 2028
Also in this update: Study completion pushed from Aug 26, 2028 to Sep 28, 2029
Karolinska InstitutetPhase 3 NCT04065009 Registry history of NCT04065009 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 31, 2024 to Mar 2027
Also in this update: Enrollment reopened; Study completion pushed from May 1, 2026 to Dec 2028
Bai-Rong XiaPhase 2 NCT05652283 Registry history of NCT05652283 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 1, 2027 to Oct 5, 2027
Novartis PharmaceuticalsPhase 1 NCT05544929 Registry history of NCT05544929 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Compugen LtdPhase 1/2 NCT06888921 Registry history of NCT06888921 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 31, 2026 to Dec 31, 2026
BicycleTx LimitedPhase 1/2 NCT04180371 Registry history of NCT04180371 on ClinicalTrials.gov (opens the registry)
Trial completed
Toray Industries, IncPhase 1 NCT03872947 Registry history of NCT03872947 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion pushed from Aug 15, 2026 to Aug 6, 2027; Primary completion date changed from estimate of Jun 15, 2026 to Aug 7, 2026
Avacta Life Sciences LtdPhase 1 NCT04969835 Registry history of NCT04969835 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 2027 to Jul 31, 2026
Jennifer KingPhase 2 NCT04876456 Registry history of NCT04876456 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Apr 30, 2026 to Sep 15, 2026; Final enrollment: 300 participants (planned 350)
Charite University, Berlin, GermanyNot applicable NCT07503054 Registry history of NCT07503054 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Oct 1, 2026 to Sep 1, 2026; Final enrollment: 1334 participants (planned 1020)
Dana-Farber Cancer InstituteNot applicable NCT05225428 Registry history of NCT05225428 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
Also in this update: Enrollment increased: 115 → 160 participants; Study completion pushed from Dec 30, 2026 to Dec 30, 2028
Medicenna Therapeutics, Inc.Phase 1/2 NCT05086692 Registry history of NCT05086692 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Northwestern UniversityNot applicable NCT05743517 Registry history of NCT05743517 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 21, 2026 to Nov 24, 2026
EMD Serono Research & Development Institute, Inc.Phase 3 NCT03815643 Registry history of NCT03815643 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 285 → 330 participants
ModeX Therapeutics, An OPKO Health CompanyPhase 1/2 NCT06239194 Registry history of NCT06239194 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 139 → 34 locations
AmgenPhase 3 NCT03937154 Registry history of NCT03937154 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to May 19, 2026; Final enrollment: 297 participants (planned 350)
Massachusetts General HospitalNot applicable NCT05470920 Registry history of NCT05470920 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Also in this update: Primary completion pushed from Apr 25, 2026 to Sep 25, 2026; Study completion pushed from May 30, 2026 to Dec 30, 2026
University Health Network, TorontoNot applicable NCT05956093 Registry history of NCT05956093 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jun 2026 to Apr 16, 2026
Institut BergoniéNot applicable NCT04906187 Registry history of NCT04906187 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2039 to Oct 2039
Also in this update: Start date pushed from Sep 2026 to Oct 2026
Weill Medical College of Cornell UniversityNot applicable NCT07764744 Registry history of NCT07764744 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 70 → 73 locations
AbbViePhase 2 NCT06890338 Registry history of NCT06890338 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 163 → 167 locations
Merck Sharp & Dohme LLCPhase 3 NCT07318558 Registry history of NCT07318558 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 18, 2026 to May 15, 2027
Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 24 → 32 participants
AstraZenecaPhase 1 NCT07402915 Registry history of NCT07402915 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 192 → 197 locations
Incyte CorporationPhase 3 NCT07214779 Registry history of NCT07214779 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 2 → 9 locations
GenmabPhase 3 NCT07564141 Registry history of NCT07564141 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 22 → 34 locations
GenmabPhase 3 NCT07225270 Registry history of NCT07225270 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 100 → 120 participants
National Cancer Institute (NCI)Phase 1 NCT06885697 Registry history of NCT06885697 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 16 locations
Perspective TherapeuticsPhase 1/2 NCT06710756 Registry history of NCT06710756 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 22 → 27 locations
Xencor, Inc.Phase 1 NCT06276491 Registry history of NCT06276491 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 91 → 94 locations
Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 16 → 21 locations
AbbViePhase 2 NCT07024784 Registry history of NCT07024784 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 92 → 86 locations
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncPhase 2 NCT05128825 Registry history of NCT05128825 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 12 → 22 locations
Pliant Therapeutics, Inc.Phase 1 NCT06270706 Registry history of NCT06270706 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 23 → 20 locations
AstraZenecaPhase 1 NCT05877599 Registry history of NCT05877599 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 31, 2026 to Aug 27, 2027
BeiGenePhase 1 NCT06257264 Registry history of NCT06257264 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 118 → 173 participants
University of Southern CaliforniaNot specified NCT07259304 Registry history of NCT07259304 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2026 to Nov 30, 2027
Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Nov 30, 2025
Klus Pharma Inc.Phase 1/2 NCT04152499 Registry history of NCT04152499 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from May 23, 2028 to Oct 2027
Also in this update: Primary completion date changed from estimate of Feb 2027 to Aug 18, 2026; Final enrollment: 584 participants (planned 530)
GenmabPhase 3 NCT06619236 Registry history of NCT06619236 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Oct 1, 2028 to Oct 9, 2027
Also in this update: Primary completion date changed from estimate of Oct 1, 2028 to Sep 23, 2026
National Cancer Institute (NCI)Phase 2 NCT05554328 Registry history of NCT05554328 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 18 → 23 locations
Alliance for Clinical Trials in OncologyNot applicable NCT07059884 Registry history of NCT07059884 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 6 locations
Instituto Portugues Oncologia de Lisboa Francisco GentilNot applicable NCT07809659 Registry history of NCT07809659 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 30, 2026 to Aug 30, 2027
OncoC4, Inc.Phase 2 NCT05446298 Registry history of NCT05446298 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Sep 6, 2026 to Jun 23, 2026
Jonsson Comprehensive Cancer CenterPhase 1 NCT07118176 Registry history of NCT07118176 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Dec 23, 2026 to Apr 15, 2026
USWM CT, LLCPhase 1 NCT04044859 Registry history of NCT04044859 on ClinicalTrials.gov (opens the registry)
Interventions modified
Rebecca ArendPhase 1 NCT07772882 Registry history of NCT07772882 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 1, 2026 to Feb 1, 2027
SWOG Cancer Research NetworkNot specified NCT03939481 Registry history of NCT03939481 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jun 30, 2026 to Dec 31, 2026
Charles University, Czech RepublicPhase 3 NCT04789694 Registry history of NCT04789694 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
ENB Therapeutics, IncPhase 1/2 NCT04205227 Registry history of NCT04205227 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2023); last known: Recruiting
Chongqing Precision Biotech Co., LtdPhase 1 NCT06010875 Registry history of NCT06010875 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Light Chain Bioscience - Novimmune SAPhase 1 NCT05403554 Registry history of NCT05403554 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jul 2024); last known: Not Yet Recruiting
Anhui Provincial HospitalPhase 3 NCT06539091 Registry history of NCT06539091 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Apr 2023); last known: Recruiting
Gynaecologisch Oncologisch Centrum ZuidPhase 2/3 NCT03458221 Registry history of NCT03458221 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
First Affiliated Hospital of Zhejiang UniversityPhase 1 NCT04778839 Registry history of NCT04778839 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot specified NCT06622798 Registry history of NCT06622798 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCSNot specified NCT06284343 Registry history of NCT06284343 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-20 | NCT07882485 Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and… | Ege University new | |
| 2026-10-20 | NCT07883551 AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant… | Catharina Ziekenhuis Eindhoven new | |
| 2026-10-13 | NCT07872644 Safety in Ovarian Cancer for Average-Risk Women - Analysis | Mercy BioAnalytics, Inc. new | |
| 2026-10-06 | NCT07860203 Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing… | Catherin Zhang new | |
| 2026-10-05 | NCT07856914 Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With… | Patrick Wagner, MD, FACS new | Phase 2 |
| 2026-09-30 | NCT07849543 Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective… | Thomas Jefferson University new | |
| 2026-09-11 | NCT07814872 A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing… | Harvard Medical School (HMS and HSDM) new | |
| 2026-09-11 | NCT07815951 Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid… | Yong He new | Phase 1 |
| 2026-09-10 | NCT07811271 Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With… | BeOne Medicines new | Phase 3 |
| 2026-09-10 | NCT07811297 A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. new | Phase 1/2 |
| Early Phase 1 | 15 | |
| Phase 1 | 199 | |
| Phase 1/2 | 134 | |
| Phase 2 | 232 | |
| Phase 2/3 | 17 | |
| Phase 3 | 100 | |
| Phase 4 | 8 |
National Cancer Institute (NCI) (51) · M.D. Anderson Cancer Center (39) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (31) · AstraZeneca (24) · Memorial Sloan Kettering Cancer Center (18) · AbbVie (15) · University Health Network, Toronto (14) · Fudan University (11) · Shanghai Gynecologic Oncology Group (11) · Mayo Clinic (10)